VistaGen Therapeutics (VTGN) Competitors $3.62 -0.03 (-0.68%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. TVRD, AUTL, LBRX, BNTC, DMAC, CTNM, ENGN, LRMR, DSGN, and KRROShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Tvardi Therapeutics (TVRD), Autolus Therapeutics (AUTL), LB Pharmaceuticals (LBRX), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), Contineum Therapeutics (CTNM), enGene (ENGN), Larimar Therapeutics (LRMR), Design Therapeutics (DSGN), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Tvardi Therapeutics Autolus Therapeutics LB Pharmaceuticals Benitec Biopharma DiaMedica Therapeutics Contineum Therapeutics enGene Larimar Therapeutics Design Therapeutics Korro Bio VistaGen Therapeutics (NASDAQ:VTGN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Does the media prefer VTGN or TVRD? In the previous week, Tvardi Therapeutics had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 0 mentions for VistaGen Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.67 beat VistaGen Therapeutics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment VistaGen Therapeutics Neutral Tvardi Therapeutics Positive Do institutionals and insiders have more ownership in VTGN or TVRD? 78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is VTGN or TVRD more profitable? VistaGen Therapeutics has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -678.79%. VistaGen Therapeutics' return on equity of -74.06% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VistaGen TherapeuticsN/A -74.06% -64.10% Tvardi Therapeutics -678.79%-565.83%-66.71% Do analysts recommend VTGN or TVRD? Tvardi Therapeutics has a consensus target price of $64.25, suggesting a potential upside of 59.71%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Tvardi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, VTGN or TVRD? VistaGen Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Which has better earnings and valuation, VTGN or TVRD? VistaGen Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistaGen Therapeutics$490K228.53-$51.42M-$1.78-2.05Tvardi Therapeutics$7.14M52.85-$70.87MN/AN/A SummaryVistaGen Therapeutics and Tvardi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.98M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-2.0522.2886.8126.71Price / Sales228.53265.33538.97202.98Price / CashN/A46.3226.3031.09Price / Book1.509.9012.676.57Net Income-$51.42M-$52.45M$3.30B$276.78M7 Day Performance3.11%5.05%3.55%1.96%1 Month Performance2.82%10.61%6.79%9.11%1 Year Performance21.26%25.03%72.30%31.60% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics0.5908 of 5 stars$3.63-0.7%N/A+21.3%$111.22M$490K-2.0440TVRDTvardi Therapeutics3.2974 of 5 stars$37.40-2.2%$64.25+71.8%N/A$358.59M$7.14M0.0080Gap UpAUTLAutolus Therapeutics3.564 of 5 stars$1.38+3.0%$9.12+560.9%-59.5%$356.63M$10.12M-1.64330LBRXLB PharmaceuticalsN/A$16.02+0.9%N/AN/A$356.39MN/A0.0016News CoverageAnalyst ForecastGap DownBNTCBenitec Biopharma1.8491 of 5 stars$13.51+0.4%$24.80+83.6%+46.0%$353.07M$80K-8.9520DMACDiaMedica Therapeutics2.5187 of 5 stars$6.98+2.3%$12.33+76.7%+62.2%$352.52MN/A-10.1220Positive NewsAnalyst UpgradeCTNMContineum Therapeutics2.7507 of 5 stars$11.27-9.8%$22.75+101.9%-33.2%$350.52M$50M-5.1231Positive NewsENGNenGene3.2066 of 5 stars$6.81-0.1%$21.00+208.4%+16.9%$349.13MN/A-3.5831LRMRLarimar Therapeutics2.9924 of 5 stars$4.48+6.7%$18.43+311.4%-26.8%$347.67MN/A-2.8730High Trading VolumeDSGNDesign Therapeutics0.0474 of 5 stars$6.35+5.0%N/A+22.2%$344.54MN/A-5.6740KRROKorro Bio1.5397 of 5 stars$34.21-5.1%$86.83+153.8%+37.6%$338.54M$2.27M-3.5170News Coverage Related Companies and Tools Related Companies TVRD Alternatives AUTL Alternatives LBRX Alternatives BNTC Alternatives DMAC Alternatives CTNM Alternatives ENGN Alternatives LRMR Alternatives DSGN Alternatives KRRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
